Pacira BioSciences Reports Q2 2026 Financial Results
Pacira BioSciences reported Q2 2026 revenue growth of 6% and closed a $140M divestiture of iovera to Zimmer Biomet, positioning the company for future innovation.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day